Examples of using Clcr in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
No data are available on patients with severe(CLCR< 30 mL/min)
35%, and 47% in subjects with mild(CLCR 50- 79 ml/min), moderate(CLCR 30- 49 ml/min), and severe(CLCR< 30 ml/min)
A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment CLcr.
Patients with CLcr less than 15 mL/min were not included in the clinical trials.
Kineret should not be used in patients with severe renal impairment(CLcr< 30 ml/ minute) see section 4.3.
Caution is recommended when dosing patients with severe renal impairment(CLcr< 30 ml/ min) see section 5.2.
The effect of renal function as measured by baseline CLcr on observed crizotinib steady-state trough concentrations(Ctrough, ss) was evaluated.
ML/min or severe renal impairment(CLcr< 30 mL/min)
For patients with severe renal impairment(CLcr< 30 mL/min)
In the absence of adequate data, Kineret should be used with caution in patients with moderate renal impairment CLcr 30 to 50 ml/ minute.
Pharmacokinetic data in patients with severe renal impairment(CLcr 15 to 29 mL/min)
The median(min-max) renal clearance of adefovir in subjects with normal renal function(Clcr> 80 ml/min)
normal with Clcr greater than 80 ml/min(n 56),
Rasagiline's pharmacokinetics characteristics in subjects with mild(CLcr 50-80 ml/ min)
of unbound ertapenem are similar in patients with mild renal insufficiency(Clcr 60 to 90 ml/ min/ 1.73 m2) compared with healthy subjects ages 25 to 82 years.
Rasagiline's pharmacokinetics characteristics in subjects with mild(CLcr 50-80 ml/min)
severe renal dysfunction(CLcr< 30 ml/min),
For patients with moderate renal impairment(CLcr≥30 and<
A starting dose of 4 mg once daily is recommended in patients with moderate renal impairment CLCR.
The use in patients with severe renal impairment(CLCR< 30 ml/min)